Please login to the form below

Not currently logged in
Email:
Password:

Novo opens doors on new US headquarters

$225m redevelopment for New Jersey life science offices

Novo Nordisk US HQ 

Novo Nordisk has completed the multi-million dollar redevelopment of its US headquarters, bolstering its presence in New Jersey.

The 731,000 square foot offices (pictured) in Mercer Country in Plainsboro were built around an existing structure and used sustainable materials to limit their environmental impact.

New Jersey Lieutenant Governor Kim Guadagno said: "The completion of this project and launch of Novo Nordisk's new headquarters is a milestone in the long and proud history of the life sciences industry here in New Jersey.

"We are gratified that this great global company has reaffirmed its belief that our state is an ideal location for a fast-growing, research-based business to plant its flag."

Features of the redeveloped building include a state-of-the-art cafeteria, a one-mile scenic walking path and special quiet focus areas where employees can work effectively.

Jurek Gruhn, president of Novo Nordisk's US business, said: "Becoming a leading healthcare company requires not only the best people in the field, but a work environment that fosters collaboration.

"Our new home provides our employees with the physical space and resources to fuel our continued commitment to provide the best possible solutions for diabetes patients in the United States."

The Danish pharma company initially plans to occupy only 75 per cent of the building's total capacity in order to leave it room for further expansion in the US.

24th April 2013

From: Research, Sales, Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...